All News
Filter News
Found 101 articles
-
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
-
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
-
Vaccine makers are working to create boosters or modify their existing vaccines to better respond to the variants.
-
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
-
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
-
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine
4/2/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that based on submitted stability data, the U.S. Food and Drug Administration has authorized the Moderna COVID-19 Vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours.
-
AstraZeneca released primary analysis that the vaccine demonstrated 76% efficacy against symptomatic COVID-19, 100% efficacy against severe or critical disease and hospitalizations and 85% efficacy against symptomatic COVID-19 in people 65 years and older.
-
Patients Recovered from COVID-19 May Require Just One Dose of mRNA Vaccine
3/9/2021
Patients previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may produce levels of antibodies against COVID-19 after a one dose of the Pfizer Inc./BioNTech SE messenger RNA (mRNA) vaccine that are equal to or higher than people not previously infected have after two doses, a new study finds.
-
CPHO Sunday Edition: Canada's Two New COVID-19 Vaccines: What You Should Know
3/7/2021
The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.
-
The company has agreed to deliver 100 million doses of the vaccines by the end of June.
-
As scientists and vaccine manufacturers continue to test their products against the variants, researchers are seeing new variants cropping up that originated in the U.S.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
-
Although designed for two doses, primary analysis of AstraZeneca and the University of Oxford’s Phase III data for its COVID-19 vaccine found it to have 76% efficacy after the first dose.
-
Although Gamestop dominated the financial news this week, surging more than 1,600% in January, Novavax actually saw greater growth in 2020, with year-to-year gains of 2,731% that exceeded those of all the coronavirus stocks.
-
British scientists suggested last week that the U.K. variant may be approximately 30% more lethal than the most common strain that came out of China. But they’re not completely sure of this yet.
-
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
-
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
-
CPHO Issue Statement Series on COVID-19: mRNA Vaccines
1/10/2021
The end of 2020 marked a turning point for Canada in our fight against COVID-19. We witnessed Canadian approval of the first two vaccines for COVID-19 - the Pfizer-BioNTech vaccine and the Moderna vaccine, and rollout of initial doses of these vaccines across the country.
-
As Operation Warp Speed struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.